- Home
- QSI vs ARCT Comparison
QSI vs ARCT Comparison
Compare QSI & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- ARCT
- Stock Information
- Founded
- QSI 2013
- ARCT 2013
- Country
- QSI United States
- ARCT United States
- Employees
- QSI N/A
- ARCT N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- ARCT Health Care
- Exchange
- QSI Nasdaq
- ARCT Nasdaq
- Market Cap
- QSI 288.2M
- ARCT 487.0M
- IPO Year
- QSI N/A
- ARCT N/A
- Fundamental
- Price
- QSI $1.92
- ARCT $15.88
- Analyst Decision
- QSI Buy
- ARCT Strong Buy
- Analyst Count
- QSI 2
- ARCT 8
- Target Price
- QSI $3.25
- ARCT $61.00
- AVG Volume (30 Days)
- QSI 24.0M
- ARCT 405.9K
- Earning Date
- QSI 02-27-2025
- ARCT 03-06-2025
- Dividend Yield
- QSI N/A
- ARCT N/A
- EPS Growth
- QSI N/A
- ARCT N/A
- EPS
- QSI N/A
- ARCT N/A
- Revenue
- QSI $2,266,000.00
- ARCT $160,399,000.00
- Revenue This Year
- QSI $193.90
- ARCT $7.33
- Revenue Next Year
- QSI $173.18
- ARCT $4.71
- P/E Ratio
- QSI N/A
- ARCT N/A
- Revenue Growth
- QSI 232.26
- ARCT N/A
- 52 Week Low
- QSI $0.61
- ARCT $14.30
- 52 Week High
- QSI $5.77
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- QSI 42.87
- ARCT 41.74
- Support Level
- QSI $2.26
- ARCT $16.03
- Resistance Level
- QSI $2.12
- ARCT $17.95
- Average True Range (ATR)
- QSI 0.25
- ARCT 1.29
- MACD
- QSI -0.11
- ARCT -0.07
- Stochastic Oscillator
- QSI 7.53
- ARCT 10.29
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.